AMLX Stock Catalyst: Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 3 LUCIDITY Trial of Avexitide

Aug 18, 2026 · 7:35am ET

The trial focused on post-bariatric hypoglycemia.

Max move

+48.6%

High of day $36.33

Sparker timei

7:35am ET

AMLX · Aug 18, 2026

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) announced positive topline results from the Phase 3 LUCIDITY clinical trial evaluating Avexitide for the treatment of post-bariatric hypoglycemia. The trial met its primary endpoint, demonstrating a statistically significant reduction in hypoglycemia episodes.

The company plans to discuss these results with regulatory authorities to determine next steps for the development program. Amylyx Pharmaceuticals has a free float of 82,381,278 shares.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time AMLX sparks.

Download Sniper App →

Catch the next AMLX-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →